{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"Grade 3 or Higher AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"AEs Resulting in Treatment Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"AEs Resulting in Dose Reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment.\n\nA SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. Relationship of each AE to study drug was determined by the Investigator.","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide (CYC) 300 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.","id":"OG000","title":"Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population was defined as all participants who received at least 1 dose of any study drug.","reportingStatus":"POSTED","timeFrame":"First dose of study drug through 30 days after last dose of drug (Up to 45 months)","title":"Number of Participants With AEs, Grade 3 or Higher AEs, AEs Resulting in Treatment Discontinuation, AEs Resulting in Dose Reduction, SAEs in RRMM Participants","type":"SECONDARY","unitOfMeasure":"Participants"}